Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

Impact · against what's priced in

Cogent Biosciences provides supportive data on bezuclastinib, reinforcing its potential as a standard of care for Non-Advanced Systemic Mastocytosis. While the primary trial success was previously reported, new evidence of disease modification via bone mineral density improvement adds incremental valuation.

COGT+0.40

No priced-in read yet